Abstract: We propose a method for learning a classifier that accurately predicts both instance and bag classes in multiple instance learning (MIL) for anomaly detection, achieving significant ...

Dana-Farber Cancer Institute investigators have developed an online, easy-to-use tool that more accurately predicts when a precursor blood condition called smoldering multiple myeloma is likely to ...

A federal judge ruled on Friday that key parts of the Pentagon’s press policy were unconstitutional. By Erik Wemple Reporting from Washington A group representing journalists who cover the Defense ...

After VSCode installed the latest February release, (Version: 1.110.0 (user setup Date: 2026-03-04T01:20:28.863Z), anytime I performed any action after launching vscode in any workspace, three or more ...

The immediate threat may be fixed, but this raises serious questions. The immediate threat may be fixed, but this raises serious questions. is a senior editor and founding member of The Verge who ...

Your developers are already running OpenClaw at home. Censys tracked the open-source AI agent from roughly 1,000 instances to over 21,000 publicly exposed deployments in under a week. Bitdefender’s ...

BENGALURU, Feb 11 (Reuters) - U.S. lawmakers chairing key House committees on Tuesday urged the State and Commerce Departments to restrict China's access to advanced chipmaking equipment, warning that ...

OpenClaw, the open-source AI assistant formerly known as Clawdbot and then Moltbot, crossed 180,000 GitHub stars and drew 2 million visitors in a single week, according to creator Peter Steinberger.

As part of its mission to preserve the web, the Internet Archive operates crawlers that capture webpage snapshots. Many of these snapshots are accessible through its public-facing tool, the Wayback ...

-- The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma -- -- A simulation model of CAR T use ahead of bispecific antibodies ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...